Larimar Advances Nomlabofusp Toward Potential FDA Approval with Rolling BLA Submission — Larimar Therapeutics, Inc.

Event summary

Larimar Therapeutics submitted the first module of its rolling Biologics License Application (BLA) for nomlabofusp, targeting completion by the second half of 2026.
Open-label study data showed sustained increases in skin frataxin levels and continued improvements in key clinical outcomes for Friedreich’s ataxia patients.
The company reported $156.3 million in cash as of June 30, 2026, with a projected runway into Q3 2027.
Dosing of the first patient in the global confirmatory Phase 3 study is expected in Q3 2026.

The big picture

Larimar’s progress with nomlabofusp reflects the broader trend in rare disease therapeutics, where targeted treatments aim to address underlying causes rather than symptoms. The company’s strategic focus on a rolling BLA submission and Phase 3 study initiation underscores its push toward commercialization amid a competitive landscape of orphan drug developers.

What we're watching

Regulatory Alignment: Whether the FDA will maintain alignment on key elements of the BLA submission, particularly the use of frataxin as a surrogate endpoint.
Clinical Momentum: The pace at which Larimar can enroll and dose participants in its global Phase 3 study, given strong patient and investigator enthusiasm.
Financial Sustainability: How Larimar manages its cash runway into Q3 2027 while advancing commercial readiness for a potential mid-2027 launch of nomlabofusp.